Sana Biotechnology/$SANA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Ticker
$SANA
Sector
Primary listing
Employees
194
Headquarters
Website
SANA Metrics
BasicAdvanced
$1.1B
-
-$1.06
1.91
-
Price and volume
Market cap
$1.1B
Beta
1.91
52-week high
$7.30
52-week low
$1.26
Average daily volume
3.9M
Financial strength
Current ratio
2.467
Quick ratio
2.173
Long term debt to equity
58.471
Total debt to equity
69.757
Profitability
EBITDA (TTM)
-191.854
Management effectiveness
Return on assets (TTM)
-26.30%
Return on equity (TTM)
-109.12%
Valuation
Price to book
7.75
Price to tangible book (TTM)
-12.29
Price to free cash flow (TTM)
-5.269
Free cash flow yield (TTM)
-18.98%
Free cash flow per share (TTM)
-0.782
Growth
Earnings per share change (TTM)
-8.07%
3-year earnings per share growth (CAGR)
-12.92%
What the Analysts think about SANA
Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.
Bulls say / Bears say
Positive feedback from the FDA INTERACT meeting in mid-2025 increased confidence in setting up a GMP master cell bank for SC451, supporting a potential IND filing as soon as 2026 and strengthening the type 1 diabetes pipeline strategy (GlobeNewswire )
Sana raised about $105 million via ATM offerings and a public equity financing in July–August 2025, extending its cash runway into the second half of 2026, ensuring funding for continued pipeline progress (NASDAQ )
The company is enrolling patients in the GLEAM and VIVID Phase 1 trials for SC291 (autoimmune diseases) and SC262 (B-cell cancers), with clinical results due in 2025, broadening and de-risking its pipeline beyond type 1 diabetes (GlobeNewswire )
Sana’s Q2 2025 operating cash burn of $81.8 million reduced its cash position from $152.5 million to $72.7 million, highlighting a high cash burn rate that requires frequent dilutive financings (GlobeNewswire )
The company reported a GAAP net loss of $93.8 million in Q2 2025, nearly double the $50.3 million loss in Q2 2024, pointing to accelerating R&D expenses and widening operating losses (Futu AI Summary )
A $44.6 million non-cash impairment charge on manufacturing facilities in Q2 2025 indicates a strategic shift away from in-house manufacturing and exposes previous risks of capital misallocation (Futu AI Summary )
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
SANA Financial Performance
Revenues and expenses
SANA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sana Biotechnology stock?
Sana Biotechnology (SANA) has a market cap of $1.1B as of October 09, 2025.
What is the P/E ratio for Sana Biotechnology stock?
The price to earnings (P/E) ratio for Sana Biotechnology (SANA) stock is 0 as of October 09, 2025.
Does Sana Biotechnology stock pay dividends?
No, Sana Biotechnology (SANA) stock does not pay dividends to its shareholders as of October 09, 2025.
When is the next Sana Biotechnology dividend payment date?
Sana Biotechnology (SANA) stock does not pay dividends to its shareholders.
What is the beta indicator for Sana Biotechnology?
Sana Biotechnology (SANA) has a beta rating of 1.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.